Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2109426
Abstract: The journey of a thousand miles in lung cancer therapy began with the discovery of actionable genomic alterations. The two most well described molecular alterations are the epidermal growth factor receptor (EGFR) mutation and ALK… read more here.
Keywords: alk; lung cancer; egfr alk; driver ... See more keywords
Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non–small cell lung cancer: an observational, retrospective, pharmacovigilance study
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2110235
Abstract: ABSTRACT Background Epidermal Growth Factor Receptor/ Anaplastic Lymphoma Kinase Tyrosine kinase inhibitors (EGFR/ALK TKIs) may provoke fatal interstitial pneumonitis (IP). The study was conducted to characterize the main characteristics of EGFR/ALK TKI-induced IP and identify… read more here.
Keywords: egfr alk; kinase inhibitors; tyrosine kinase; alk ... See more keywords
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-006243
Abstract: Background Previous studies found that lung adenocarcinomas (LUAD) with EGFR-positive and ALK-positive were less responsive to immunotherapy, which may be associated with a suppressive tumor immune microenvironment (TIME). Given the discordance in the TIME between… read more here.
Keywords: bms; egfr alk; alk negative; alk positive ... See more keywords
Durvalumab May Be Effective in Patients with EGFR+/ALK+ NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-049
Abstract: PD-L1 blockade with durvalumab achieves responses in patients with EGFR+/ALK+ and EGFR-/ALK- NSCLC. read more here.
Keywords: egfr alk; durvalumab may; alk nsclc; may effective ... See more keywords
Mutation and treatment profiles of patients with concurrent EGFR and ALK actionable mutations (muts).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3138
Abstract: 3138 Background: Actionable muts in EGFR and ALK define two molecular subtypes sensitive to EGFR-TKIs and ALK-TKIs, respectively. Although generally mutually exclusive, they did co-exist in some cases. However, when and how do they co-exist… read more here.
Keywords: alk muts; alk; egfr tkis; egfr ... See more keywords
The role of low dose aspirin, vitamin D, or metformin in EGFR, ALK, and ROS positive non-small cell lung cancer: A single institution retrospective analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e20656
Abstract: e20656 Background: Tyrosine kinase inhibitor (TKI) is the backbone therapy for EGFR, ALK and ROS positive (pos) non-small cell lung cancer (NSCLC). Metformin has shown to sensitize EGFR resistant lung cancer cells in vitro through… read more here.
Keywords: alk ros; use; lung cancer; egfr alk ... See more keywords
Effect of high patient out-of-pocket (OOP) cost for oral tyrosine kinase inhibitors (TKIs) on survival in EGFR and ALK positive stage IV non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.27_suppl.3
Abstract: 3 Background: Patients with EGFR+ or ALK+ NSCLC benefit from oral TKIs, but high patient OOP TKI costs could negatively impact survival by reducing likelihood of continuing TKI therapy. We assessed the association of high… read more here.
Keywords: egfr alk; oop; tki therapy; tki costs ... See more keywords
Biomarker testing in non-small cell lung cancer (NSCLC): An assessment of current practices in precision oncology in the community setting—A trial of the ECOG-ACRIN cancer research group (EAQ161CD).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e18649
Abstract: e18649 Background: Molecular biomarker testing is integral to NSCLC cancer care, but adoption and testing practices in the community are varied and often suboptimal. Testing practices, such as standard testing protocols and results turnaround time… read more here.
Keywords: community; testing practices; cancer; oncology ... See more keywords
Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15051505
Abstract: Simple Summary Drugs acting against specific molecular alterations in cancer cells are tested in clinical studies and found to be highly efficacious in some patients with lung cancer. However, the true benefit in patients treated… read more here.
Keywords: study; egfr alk; real world;
PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience.
Sign Up to like & getrecommendations! Published in 2018 at "Neoplasma"
DOI: 10.4149/neo_2018_171225n843
Abstract: In contrast to other countries with predominantly white populations, Russian smoking-related lung cancers (LC) are mainly squamous cell carcinomas and approximately half lung adenocarcinomas (AdCa) are not related to tobacco consumption. Given that smoking significantly… read more here.
Keywords: alk kras; egfr alk; alk; mutation ... See more keywords